213 related articles for article (PubMed ID: 3023609)
21. Evidence that the delta-selective alkylating agent, fit, alters the mu-noncompetitive opiate delta binding site.
Rothman RB; Danks JA; Herkenham M; Jacobson AE; Burke TR; Rice KC
Neuropeptides; 1985 Jun; 6(3):227-37. PubMed ID: 2991807
[TBL] [Abstract][Full Text] [Related]
22. Antipodal alpha-N-(methyl through decyl)-N-normetazocines (5,9 alpha-dimethyl-2'-hydroxy-6,7-benzomorphans): in vitro and in vivo properties.
May EL; Aceto MD; Bowman ER; Bentley C; Martin BR; Harris LS; Medzihradsky F; Mattson MV; Jacobson AE
J Med Chem; 1994 Sep; 37(20):3408-18. PubMed ID: 7932569
[TBL] [Abstract][Full Text] [Related]
23. Dihydromorphine-peptide hybrids have mu receptor antagonistic and delta receptor agonistic activity on the mouse vas deferens and bind with high affinity to opioid receptors in rat brain.
Smith CB; Medzihradsky F; Woods JH
NIDA Res Monogr; 1986; 75():189-92. PubMed ID: 2828970
[TBL] [Abstract][Full Text] [Related]
24. 2,5-Dimethyl-2'-hydroxy-9 alpha- and 9 beta-(3-methylbutyl)-6,7-benzomorphans and N-substituted compounds in the 9 alpha-(3-methylbutyl) series: chemistry, pharmacology, and biochemistry.
Jacobson AE; Rice KC; Burke TR; Lupinacci L; Mattson MV; Aceto MD; Harris LS
J Pharm Sci; 1987 Mar; 76(3):248-52. PubMed ID: 3035172
[TBL] [Abstract][Full Text] [Related]
25. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors.
Portoghese PS; Larson DL; Sayre LM; Yim CB; Ronsisvalle G; Tam SW; Takemori AE
J Med Chem; 1986 Oct; 29(10):1855-61. PubMed ID: 3020244
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of delta receptor mediation of supraspinal opioid analgesia by in vivo protection against the beta-funaltrexamine antagonist effect.
Sánchez-Blázquez P; Garzón J
Eur J Pharmacol; 1989 Jan; 159(1):9-23. PubMed ID: 2565240
[TBL] [Abstract][Full Text] [Related]
27. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
28. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F
J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176
[TBL] [Abstract][Full Text] [Related]
29. Probes for narcotic receptor-mediated phenomena. 27. Synthesis and pharmacological evaluation of selective delta-opioid receptor agonists from 4-[(alphaR)-alpha-(2S,5R)-4-substituted-2, 5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and their enantiomers.
Furness MS; Zhang X; Coop A; Jacobson AE; Rothman RB; Dersch CM; Xu H; Porreca F; Rice KC
J Med Chem; 2000 Aug; 43(16):3193-6. PubMed ID: 10956228
[TBL] [Abstract][Full Text] [Related]
30. Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: evidence for a two-site allosteric model.
Rothman RB; Bowen WD; Bykov V; Schumacher UK; Pert CB; Jacobson AE; Burke TR; Rice KC
Neuropeptides; 1984 May; 4(3):201-15. PubMed ID: 6087189
[TBL] [Abstract][Full Text] [Related]
31. N,N-dialkylated leucine enkephalins as potential delta opioid receptor antagonists.
Lovett JA; Portoghese PS
J Med Chem; 1987 Jul; 30(7):1144-9. PubMed ID: 3037078
[TBL] [Abstract][Full Text] [Related]
32. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
33. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
34. Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
Schoenecker JW; Takemori AE; Portoghese PS
J Med Chem; 1986 Oct; 29(10):1868-71. PubMed ID: 3020246
[TBL] [Abstract][Full Text] [Related]
35. Delta opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for delta receptor subtypes.
Portoghese PS; Sultana M; Nelson WL; Klein P; Takemori AE
J Med Chem; 1992 Oct; 35(22):4086-91. PubMed ID: 1331455
[TBL] [Abstract][Full Text] [Related]
36. Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
Márki A; Monory K; Otvös F; Tóth G; Krassnig R; Schmidhammer H; Traynor JR; Roques BP; Maldonado R; Borsodi A
Eur J Pharmacol; 1999 Oct; 383(2):209-14. PubMed ID: 10585536
[TBL] [Abstract][Full Text] [Related]
37. Opioid agonist and antagonist antinociceptive properties of [D-Ala2,Leu5,Cys6]enkephalin: selective actions at the deltanoncomplexed site.
Qi JA; Bowen WD; Mosberg HI; Rothman RB; Porreca F
J Pharmacol Exp Ther; 1990 Nov; 255(2):636-41. PubMed ID: 2173752
[TBL] [Abstract][Full Text] [Related]
38. Comparison of "selective" opiate receptor antagonists on the isolated mouse vas deferens.
Smith CB; Bennett-Kelly L; Woods JH
Neuropeptides; 1984 Dec; 5(1-3):161-4. PubMed ID: 6099488
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the antinociceptive action of mu and delta opioid receptor ligands in the periaqueductal gray matter, medial and paramedial ventral medulla in the rat as studied by the microinjection technique.
Jensen TS; Yaksh TL
Brain Res; 1986 May; 372(2):301-12. PubMed ID: 2871901
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist.
Schmidhammer H; Burkard WP; Eggstein-Aeppli L; Smith CF
J Med Chem; 1989 Feb; 32(2):418-21. PubMed ID: 2536439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
